MAPK3 and breast carcinoma: A recent report showed that the type II IL4R was expressed and activated in human breast cancer and the metastatic capacity was decreased by knocking down IL4Rα, therefore inactivating Erk1/2, Akt and mTor induced reduction in breast cancer proliferation and survival [35].